LEVER Trial: Levonorgestrel Intrauterine Device Alone or in Combination with an mTORC1 Inhibitor to Overcome Progesterone Resistance in Atypical Hyperplasia or Stage Ia Grade 1 Endometrioid Endometrial Cancer

Authors

• Ernesto Saul Flores Barrera, The University of Texas MD Anderson Cancer Center
• Tina Alvarado, The University of Texas MD Anderson Cancer Center
• Gaby Granda, The University of Texas MD Anderson Cancer Center
• Sara Hull, The University of Texas MD Anderson Cancer Center
• Larissa A. Meyer, The University of Texas MD Anderson Cancer Center
• Melinda Yates, The University of Texas MD Anderson Cancer Center
• Shannon N. Westin, The University of Texas MD Anderson Cancer Center

Files

Publisher

The University of Texas MD Anderson Cancer Center

City

Houston

Keywords

Endometrial Cancer; Everolimus; Progesterone; Levonorgestrel

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.

Program Affiliation

Partnership for Careers in Cancer Science and Medicine

Recommended Citation

Flores Barrera, Ernesto Saul; Alvarado, Tina; Granda, Gaby; Hull, Sara; Meyer, Larissa A.; Yates, Melinda; and Westin, Shannon N., "LEVER Trial: Levonorgestrel Intrauterine Device Alone or in Combination with an mTORC1 Inhibitor to Overcome Progesterone Resistance in Atypical Hyperplasia or Stage Ia Grade 1 Endometrioid Endometrial Cancer" (2021). Summer Experience 2021. 79.
https://openworks.mdanderson.org/sumexp21/79